Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1

Leukemia

Volumn 18, Issue 7, 2004, Pages 1246-1251

  Tang, R ^a   Faussat, A M ^a   Majdak, P ^a   Perrot, J Y ^b   Chaoui, D ^a   Legrand, O ^a   Marie, Jean Pierre ^a  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

Acute myeloid leukemia; HDAC inhibitors; MRP1; P gp; Valproic acid

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; CYTARABINE; FLICE INHIBITORY PROTEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID; CARRIER PROTEIN; CFLAR PROTEIN, HUMAN; ENZYME INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; SIGNAL PEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN K 562; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; ACUTE DISEASE; CELL CULTURE; CELL DIVISION; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; METABOLISM; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PATHOLOGY; TUMOR CELL LINE;

ACUTE DISEASE; APOPTOSIS; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL DIVISION; CELL LINE, TUMOR; CYTARABINE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 3142692649     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403390     Document Type: Article

References (27)

1. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91: 3497-3504.
2. Germann UA. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996; 32A: 927-944.
3. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 1999; 94: 1046-1056.
4. Legrand O, Perrot JY, Simonin G, Baudard M, Marie JP. JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. Blood 2001; 97: 502-508.
5. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202, (review).
6. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discovery 2002; 1: 287-299.
7. Kitamura K, Hoshi S, Koike M, Kiyoi H, Saito H, Naoe T. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br J Haematol 2000; 108: 696-702.
8. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001; 20: 1860-1872.
9. Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 2002; 8: 1206-1212.
10. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9 (Part 1): 3578-3588.
11. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969-6978.
12. Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leukemia Res 2002; 26: 495-502.
13. Lacombe F, Belloc F, Dumain P, Puntous M, Lopez F, Bernard P et al. Quantitation of resistance of leukemic cells to cytosine arabinoside from BrdUrd/DNA bivariate histograms. Cytometry 1992; 13: 730-738.
14. Radosevic N, Delmer A, Tang R, Marie JP, Ajchenbaum-Cymbalista F. Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure. Leukemia 2001; 15: 559-566.
15. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000; 95: 2118-2125.
16. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003; 101: 3236-3239.
17. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D et al. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 2003; 63: 2118-2126.
18. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies; KA, O'Reilly LA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460-4471.
19. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2-7.
20. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-4062.
21. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18: 7016-7025.
22. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164, (review).
23. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003; 102: 3765-3774.
24. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002; 16: 1331-1343.
25. Yu C, Subler M, Rahmani M, Reese E, Krystal G, Conrad D et al. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2003; 2: 544-551.
26. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003; 102: 652-658.
27. Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M et al. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 2003; 17: 2122-2129.